Market Overview

UPDATE: Citigroup Lowers PT on Quest Diagnostics Following Disappointing 3Q13 Results

Share:
Related DGX
The Market In 5 Minutes
Benzinga's Top Upgrades, Downgrades For April 21, 2017

In a report published Friday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Quest Diagnostics (NYSE: DGX), but lowered the price target from $64.00 to $60.00.

In the report, Citigroup noted, “DGX previewed disappointing 3Q13 results this morning after mounting a spirited defense of its guidance on its 7/18/13 2Q13 conference call. More recently, on 9/18/13 we hosted a management roadshow in Chicago. The key takeaway from our note was as follows ‘Mgmt is sticking to its 2014 double-digit EPS growth target while maintaining that they've seen no material recent change in industry trends.' Obviously, it's difficult to square these outlooks with the reported results.”

Quest Diagnostics closed on Thursday at $58.66.

Latest Ratings for DGX

DateFirmActionFromTo
Apr 2017Raymond JamesUpgradesMarket PerformOutperform
Mar 2017Bank of AmericaUpgradesUnderperformNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Citigroup Gary TaylorAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!